Faculty profile

Peter Kannu

ResearcherDevelopmental and Stem Cell BiologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Peter Kannu

Researcher

Developmental and Stem Cell Biology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
5 publications in the last five years, latest in 2026.
Principal investigator on 3 research grants (3 CIHR), most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

752

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Bone Fracture Repair Met Receptor Mouse Models Osteofibrous Dysplasia Cell Division Dna Replication Dwarfism

Latest papers

Palovarotene impact on fibrodysplasia ossificans progressiva (FOP): data from month 48 of the phase III MOVE trial.
JBMR plus · 2026
Evaluation of the diagnostic accuracy of exome sequencing and its impact on diagnostic thinking for patients with rare disease in a publicly funded health care system: A prospective cohort study
Genetics in Medicine · 2024
Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023

All 49 publications

Latest funding

Recommendations for the Design, Maintenance, and Utilization of Rare Disease Patient Registries: Guidance for Patient Partners, Clinicians, Researchers, and Other Knowledge Users
CIHR · 2025 · Co-investigator
$566,100
MET signalling in bone and fracture healing
CIHR · 2019 · Nominated PI
$738,226
Novel determinants of CMG DNA helicase activity and their impact on Primordial Dwarfism
CIHR · 2018 · Principal investigator
$956,250

All 4 grants and awards

49 publications.

Palovarotene impact on fibrodysplasia ossificans progressiva (FOP): data from month 48 of the phase III MOVE trial.

Pignolo RJ, Hsiao EC, Al Mukaddam M, Baujat G, Berglund SK, Cheung AM, De Cunto C, Delai P, Haga N, Kannu P, Mancilla EE, Marino R, Shih F, Strahs A, Kaplan FS

JBMR plus2026

DOI: 10.1093/jbmrpl/ziag141 PMID: 42770123

Evaluation of the diagnostic accuracy of exome sequencing and its impact on diagnostic thinking for patients with rare disease in a publicly funded health care system: A prospective cohort study

Hartley T, Marshall D, Acker M, Fooks K, Gillespie MK, Price EM, Graham ID, White-Brown A, MacKay L, Macdonald SK

Genetics in Medicine202410 citations

DOI: 10.1016/j.gim.2023.101012

Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).

Pignolo RJ, Hsiao EC, Al Mukaddam M, Baujat G, Berglund SK, Brown MA, Cheung AM, De Cunto C, Delai P, Haga N, Kannu P, Keen R, Le Quan Sang KH, Mancilla EE, Marino R, Strahs A, Kaplan FS

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2023

DOI: 10.1002/jbmr.4762 PMID: 36583535

Bridging clinical care and research in Ontario, Canada: Maximizing diagnoses from reanalysis of clinical exome sequencing data

Hartley T, Soubry É, Acker M, Osmond M, Couse M, Gillespie MK, Ito Y, Marshall AE, Lemire G, Huang L

Clinical Genetics202315 citations

DOI: 10.1111/cge.14262

Hypomorphic GINS3 variants alter DNA replication and cause Meier-Gorlin syndrome.

McQuaid ME, Ahmed K, Tran S, Rousseau J, Shaheen R, Kernohan KD, Yuki KE, Grover P, Dreseris ES, Ahmed S, Dupuis L, Stimec J, Shago M, Al-Hassnan ZN, Tremblay R, Maass PG, Wilson MD, Grunebaum E, Boycott KM, Boisvert FM, Maddirevula S, Faqeih EA, Almanjomi F, Khan ZU, Alkuraya FS, Campeau PM, Kannu P, Campos EI, Wurtele H

JCI insight2022

DOI: 10.1172/jci.insight.155648 PMID: 35603789

Hardened Hope: Care Advances for Fibrodysplasia Ossificans Progressiva.

Kannu P, Levy CE

The Journal of pediatrics2021First author

DOI: 10.1016/j.jpeds.2021.02.035 PMID: 33896449

ELOVL4 with erythrokeratoderma: A pediatric case and emerging genodermatosis.

Croitoru D, Lu JD, Lara-Corrales I, Kannu P, Pope E

American journal of medical genetics. Part A2021

DOI: 10.1002/ajmg.a.62136 PMID: 33655653

Evolving Management of Fibrodysplasia Ossificans Progressiva.

Kannu P, Levy CE

The Journal of pediatrics2021First author

DOI: 10.1016/j.jpeds.2021.02.037 PMID: 33896451

Lost bones: differential diagnosis of acro-osteolysis seen by the pediatric rheumatologist.

Limenis E, Stimec J, Kannu P, Laxer RM

Pediatric rheumatology online journal2021

DOI: 10.1186/s12969-021-00596-0 PMID: 34261502

Diagnostic utility of next-generation sequence genetic panel testing in children presenting with a clinically significant fracture history.

Harrington J, AlSubaihin A, Dupuis L, Kannu P, Mendoza-Londono R, Howard A

Archives of osteoporosis2021

DOI: 10.1007/s11657-021-00943-4 PMID: 34091789

Something wrong or missing on this profile? Suggest a correction

Peter Kannu

Research

Latest papers

Latest funding

Palovarotene impact on fibrodysplasia ossificans progressiva (FOP): data from month 48 of the phase III MOVE trial.

Evaluation of the diagnostic accuracy of exome sequencing and its impact on diagnostic thinking for patients with rare disease in a publicly funded health care system: A prospective cohort study

Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).

Bridging clinical care and research in Ontario, Canada: Maximizing diagnoses from reanalysis of clinical exome sequencing data

Hypomorphic GINS3 variants alter DNA replication and cause Meier-Gorlin syndrome.

Hardened Hope: Care Advances for Fibrodysplasia Ossificans Progressiva.

ELOVL4 with erythrokeratoderma: A pediatric case and emerging genodermatosis.

Evolving Management of Fibrodysplasia Ossificans Progressiva.

Lost bones: differential diagnosis of acro-osteolysis seen by the pediatric rheumatologist.

Diagnostic utility of next-generation sequence genetic panel testing in children presenting with a clinically significant fracture history.

Recommendations for the Design, Maintenance, and Utilization of Rare Disease Patient Registries: Guidance for Patient Partners, Clinicians, Researchers, and Other Knowledge Users

MET signalling in bone and fracture healing

Novel determinants of CMG DNA helicase activity and their impact on Primordial Dwarfism

Undiagnosed systemic inflammatory disease - a Canadian Roadmap for Genomic sequencing

Frequent collaborators

Andrew Howard

Andrew Howard

Gregory Costain

Jennifer Harrington

Taila Hartley

Lauren Chad

David Chitayat

Rosanna Weksberg

Jodi Warman Chardon

Jagdeep Walia

Ashish Marwaha

Sarah Bowdin

Gail Graham

Mark Tarnopolsky

Resham Ejaz

Ronald Cohn

Beth Potter

Michael Geraghty

Ayeshah Chaudhry

Abdul Noor

Erika Tavares

Raymond Kim

Rylan Egan

Patricia Parkin

Nomazulu Dlamini

Kristin Kernohan

Ashish Marwaha

Sevan Hopyan

Deborah Marshall

Michael Brudno

Filio Billia

Maxime Bouchard

Brian Raught

Elysa Widjaja

Martin Offringa

Frank Rauch

Xiang-Jiao Yang

Jacek Majewski

Etienne Sochett

Christoph Licht